Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSetting